Glucose <  mg/dl
Fasting serum glucose =<  mg/dL
Within less than or equal to  days prior to registration: Fasting serum glucose =<  mg/dL
Diabetics are allowed if:\r\n* Fasting blood glucose (FBG) =<  mg/dL (mmol/L),\r\nOR\r\n* HbAc =< %
Fasting glucose =<  mg/dL and hemoglobin Ac (HbAc) < %
Fasting plasma glucose [fasting is defined as no calorific intake for at least  hours]:\r\n* >=  mg/dL for those patients without a pre-existing diagnosis of type  diabetes mellitus\r\n* >= mg/dL for those patients with a pre-existing diagnosis of type  diabetes mellitus
Fasting glucose =<  mg/dL (. mmol/L)
Fasting plasma glucose <  mg/dL/. mmol/L
Fasting serum glucose (=<  mg/dL)
Fasting glucose under control (<  mg/dL [. mmol/L])
Poorly-controlled diabetes mellitus, as defined as fasting serum glucose concentration over  mg/dl or glycated hemoglobin (AC) over .%.
Uncontrolled diabetes as defined by fasting serum glucose > .x ULN
Uncontrolled diabetes as defined by fasting glucose >. times the ULN. Note: these participants can be included after initiation or adjustment of glucose-lowering medication.
Fasting plasma glucose <  mg/dL / . mmol/L and glycosylated hemoglobin (HbAc) =< % (both criteria have to be met)
Glucose, serum <  mg/dL
Fasting plasma glucose (FPG) =<  mg/dL or . mmol/L
Diagnosis of diabetes mellitus defined as\r\n* Fasting blood glucose >  mg/dl or\r\n* Random blood glucose >  mg/dl\r\n* Hemoglobin AC > .%
Patients with uncontrolled diabetes or fasting blood glucose >  mg/dL may enroll but will not be evaluable for PET imaging
Fasting serum glucose (=<  mg/dL)
Poorly controlled diabetes (defined as fasting glucose level >  mg/dL) despite attempts to improve glucose control by fasting duration and adjustment of medications; patients with diabetes will preferably be scheduled for PET/CT imaging in the morning, and instructions for fasting and use of medications will be provided in consultation with the patients primary physicians
Fasting plasma glucose =<  mg/dL
Obtained =<  days prior to registration: Fasting serum glucose =< . x ULN
Fasting serum glucose =<  mg/dL.
Fasting blood glucose (FBG) <  mg/dL
Fasting plasma glucose =<  mg/dL (=< . mmol/L)
Fasting serum glucose (=<  mg/dL)
Fasting serum glucose =<  mg/dL
Fasting glucose =<  mg/dL (CTCAE grade  baseline)
History of Type  or  diabetes mellitus requiring regular medication (other than oral hypoglycemic agents) or fasting glucose ?  mg/dL at the Pre-Study visit
Fasting plasma glucose =<  mg/dL (=< . mmol/L)
Fasting serum glucose (=< mg/dL)
Metabolic: fasting serum glucose (=<  mg/dL)
Fasting serum glucose (=<  mg/dL)
CERITINIB INCLUSION CRITERIA: Fasting plasma glucose =<  mg/dL (=< . mmol/L)
Fasting plasma glucose =<  mg/dL (=< . mmol/L)
Fasting serum glucose =<  mg/dL
History of Type  or  diabetes mellitus requiring regular medication (other than oral hypoglycemic agents including metformin) or fasting glucose ?  mg/dL
Glucose >=  mg/dL
For patients without known type II diabetes, the following is required at screening:\r\n* Fasting plasma glucose =<  mg/dL (. mmol/L) and glycosylated hemoglobin (HbAc) < . % or International Federation of Clinical Chemistry (IFCC) <  mmol/mol
Fasting plasma glucose =<  mg/dL (=< . mmol/L)
Fasting serum glucose =<  mg/dL
Fasting plasma glucose =<  mg/dL (. mmol/L)
Glucose <  mg/dL
Known diabetes (type  or ), fasting glucose > or equal to . mmol/L ( mg/dL), or HgbAC > .
Uncontrolled diabetes mellitus, or subjects with either of the following:\r\n* Fasting blood glucose (FBG defined as fasting for at least  hours) >=  mg/dL (. mmol/L), or\r\n* Glycosylated hemoglobin measurement (HbAc) >= %
Within  weeks of preregistration: Blood glucose =<  mg/dL fasting or =<  mg/dL nonfasting
ELIGIBILITY CRITERIA FOR REGISTRATION: blood glucose =<  mg/dL fasting or =<  mg/dL nonfasting (within one week of registration if patient postop, otherwise within two weeks of registration)
EXCLUSION CRITERIA FOR REGISTRATION: subjects with known diabetes, fasting glucose over  mg/dL or random glucose over  mg/dL and those taking metformin, sulfonylureas, thiazolidinediones or insulin for any reason; either fasting OR random glucose may be used to determine eligibility
Fasting blood sugar =<  mg/dL; patient may be on diabetic medication to achieve glucose control\r\n* Documented fasting blood sugars =<  mg/dL\r\n* Diabetic subjects who have recently had their glycemic control regimens adjusted and have documented fasting blood glucose concentrations =<  mg/dL may be considered regardless of hemoglobin AC (HgbAc) value, if per investigator discretion the subject is considered to have adequate glycemic function
Fasting plasma glucose =<  mg/dL (. mmol/L) (Gedatolisib can cause hyperglycemia)
Fasting plasma glucose =<  mg/dL
Fasting plasma glucose (FPG) =<  mg/dL or =< . mmol/L
Fasting plasma glucose (FPG) =< mg/dL or =< . mmol/L
Patient has fasting plasma glucose (FPG) ? mg/dL (. mmol/L) and glycosylated hemoglobin (HbAc) ? .% (both criteria have to be met)
TREATMENT: Patients who have poorly controlled diabetes (defined as fasting blood glucose of >  mg/dL (Common Terminology Criteria for Adverse Events [CTCAE] grade >= ) and glycated hemoglobin (HgAc) > % are ineligible to receive treatment with everolimus on study; patients with fasting blood glucose >  mg/dL may be eligible if the HgAc < %, per PI discretion
Patients with uncontrolled diabetes mellitus (fasting blood glucose controlled by medication, =<  mg/dL allowed)
Subjects with fasting plasma glucose ?  mg/dL and HbAc < . % at screening\n             Subjects with fasting plasma glucose ? mg/dL and HbAc ? . % at screening for\n             the Diabetes Expansion Cohort.
Fasting glucose <  mg/dL obtained within  days prior to sub-study registration
Fasting glucose <  mg/dL obtained within  days prior to Step  re-registration
Fasting glucose =<  mg/dL
Within  days of subject registration: Fasting plasma glucose =<  mg/dL or . mmol/L\r\n* (NOTE: Fasting whole blood glucose testing is acceptable if fasting plasma glucose is not feasible)
Uncontrolled diabetes as defined by fasting serum glucose > . x ULN
Fasting blood glucose =<  mg/dL within  days prior to registration
Fasting plasma glucose (FPG) =<  mg/dL
Fasting serum glucose <  mg/dl ( mmol/l)
Fasting glucose <  mg/dL
Patients with abnormal fasting glucose values at screening will be excluded (fasting glucose >= ); in addition, patients with type  diabetes will also be excluded; however, patients with type  diabetes will be allowed if diagnosed >=  months prior to enrollment, and if presenting with hemoglobin AC (HbAC) =< % at screening
Baseline fasting blood glucose must be =<  mg/dL and hemoglobin Ac less than .% (with or without the use of anti-diabetic medications)
Poorly controlled diabetes (defined as fasting glucose level >  mg/dL) despite attempts to improve glucose control by fasting duration and adjustment of medications
Fasting plasma glucose =<  mg/dL (. mmol/L)
Normal fasting glucose
Diabetes or elevated fasting blood sugar either by history or by hemoglobin Ac (HgbAc) greater than .% or fasting serum glucose greater than  mg/dL on screening labs; if fasting serum glucose is greater than mg/dL on screening labs, this test will be repeated to confirm the results
Uncontrolled diabetes as defined by fasting serum glucose > . x ULN
Fasting plasma glucose <  mg/dl (may be on antiglycemic agents other than insulin); fasting glucose measurement must be obtained at least  hours after the most recent caloric intake
Fasting glucose value ?  mg/dL (CTCAE Grade  baseline)
Patients must not have uncontrolled diabetes mellitus (defined by fasting serum glucose > . x ULN) obtained within  days prior to registration; optimal glucose control must be achieved before registration and monitored during protocol treatment
Uncontrolled diabetes, as evidenced by fasting serum glucose level > mg/dL
Fasting plasma glucose < . mmol/L (<  mg/dL) and HbAc < .%. Inclusion criteria only for patients entering phase Ib escalation and phase II:
Patients with uncontrolled type II (hemoglobin AC [HbAc] > % assessed locally) as judged by the investigator or abnormal fasting glucose value defined as >  mg/dL (>  mmol/L)
Fasting plasma glucose (FPG) =<  mg/dL or =< . mmol/L
Fasting serum glucose =<  mg/dL
Fasting glucose <  mg/dL
Baseline fasting glucose of <  mg/dl ( mmol/L)
Known diabetes (type  or ) or baseline fasting glucose >=  mg/dl ( mmol/L)
Fasting plasma glucose (FPG) <  mg/dL/. mmol/L, where fasting is defined as no food intake for  hours prior to measurement
Type I diabetes mellitus (DM), type II DM patients requiring insulin for chronic blood glucose control, and any patients with a fasting blood glucose >  mg/dL (. mmol/L) at screening will be excluded
Fasting plasma glucose =<  mg/dL (. mmol/L)
Diabetes mellitus on active treatment, or subjects with either of the following:\r\n* Fasting blood glucose (FBG) >=  mg/dL (. mmol/L), or \r\n* Hemoglobin AC (HbAc) >= .%
Fasting glucose <  mg/dL
Patients with a fasting blood glucose >=  mg/dL (. mmol/L); patients with diabetes mellitus are eligible if they require oral agents only and have a fasting blood glucose =<  mg/dL; patients with a history of diabetes mellitus who require daily long-acting or mealtime insulin are not eligible; patients who have previously required treatment for hyperglycemia due to steroids or other medications are eligible as long as they have not required insulin or any other oral agent within  months prior to study enrollment
At least  weeks ( days) prior to registration: Fasting plasma glucose (FPG) <  mg/dL/. mmol/L
Fasting glucose <  mg/dL; patients with diabetes are allowed to participate, provided that their blood glucose is <  mg/dL upon enrollment
Uncontrolled diabetes, as defined by fasting serum glucose > . times ULN*
Fasting plasma glucose <  mg/dl (may be on antiglycemic agents other than insulin); fasting glucose measurement must be obtained at least  hours after the most recent caloric intake
Uncontrolled diabetes (as defined by fasting glucose >=  mg/dL) and/or insulin-dependent diabetes; fasting glucose measurement must be obtained at least  hours after the most recent caloric intake; patients currently requiring the use of antiglycemic agents (other than insulin) may be enrolled if fasting glucose <  mg/dL
Fasting plasma glucose =<  mg/dL (. mmol/L), if not consider initiation of metformin treatment prior to study treatment
Obtained within  weeks from study entry: Fasting plasma glucose =<  mg/dL
Type I or II diabetes mellitus with HbAc > .% or fasting plasma glucose >  mg/dL at screening.
Patients with diabetes, OR fasting blood glucose level >=  mg/dl\r\n* NOTE: patients with drug induced diabetes are eligible if the offending drug has been stopped and the patients fasting blood glucose level has recovered to <  mg/dl
Uncontrolled diabetes mellitus as defined by a fasting blood glucose > ULN.
ARM A: Fasting plasma glucose =<  mg/dL (. mmol/L); ARM B: Fasting plasma glucose =<  mg/dL (. mmol/L); hemoglobin Ac (HbAc) =< %; ARMS C and D: Fasting plasma glucose =<  mg/dL
f. Poorly controlled diabetes (fasting blood glucose >  mg/dL)
Uncontrolled diabetes as defined by fasting glucose >. times the ULN. Note: these participants can be included after initiation or adjustment of glucose-lowering medication
Fasting serum glucose =<  mg/dl (fasting is defined as at least  hours without oral intake)
Fasting blood glucose of ?  mg/dL (. mmol/L).
Fasting blood glucose of ?  mg/dL (. mmol/L).
Fasting plasma glucose =<  mg/dL (. mmol/L)
Patients with diabetes mellitus requiring insulin treatment and/or with clinical signs or with Fasting Plasma Glucose (FPG) ?  mg/dL / . mmol/L
Fasting plasma glucose > mg/dL or > . mmol/L
Patient does not have uncontrolled diabetes mellitus (fasting blood glucose >  mg/dL)
Patient with diabetes mellitus: fasting glucose =<  mg/dL and hemoglobin Ac (HbAc) =< %
Fasting glucose of ? mg/dL (. mmol/L).
Fasting plasma glucose =<  mg/dL (=< . mmol/L)
For all patients (regardless of known diabetes) the following is required at screening: fasting blood glucose =<  mg/dL (. mmol/L) and glycosylated hemoglobin (HbAc) =< .%
Fasting serum glucose =<  mg/dL
Uncontrolled diabetes mellitus (fasting plasma glucose >  mg/dL)
Glycated hemoglobin (HgbAc) ?  %; Fasting Plasma Glucose (FPG) ? . mmol/L ( mg/dL).
Fasting glucose > . mmol/L ( mg/dL). or HbAc > .%.
Fasting glucose less than or equal to (</=)  milligrams per deciliter (mg/dL)
Fasting glucose <  mg/dL (. mmol/L).
Fasting plasma glucose < . mmol/L (< mg/dL) and HbAC < %
Patients with abnormal fasting glucose values (values > upper limit of normal [ULN] or < LLN) at screening will be excluded; in addition, patients with type  diabetes will also be excluded; however, patients with type  diabetes will be allowed if diagnosed >=  months prior to enrollment, and if presenting with a normal fasting glucose value and a regular hemoglobin AC (HbAC) =< % at screening
Fasting plasma glucose (FPG) ?  mg/dL or ? . mmol/L
Subjects with fasting glucose > mg/dL in  independent measurements or glycated hemoglobin (HbAc) ? %
Fasting serum glucose < . x ULN obtained =<  days prior to registration
Uncontrolled diabetes as defined by fasting serum glucose >. x ULN
Fasting plasma glucose =<  mg/dL (. mmol/L)
Fasting glucose =<  mg/dL
Fasting plasma glucose (FPG) =<  mg/dL or . mmol/L
The participant has fasting serum glucose less than or equal to  mg/dL, and hemoglobin AC less than or equal to %.
Current diagnosis of type I or II diabetes mellitus or fasting blood glucose level > mg/dL at screening, or HbAc %
Uncontrolled diabetes as defined by fasting serum glucose > . x ULN
The participant has fasting serum glucose <  milligram/deciliter (mg/dL) and hemoglobin Ac (HgbAc)? . If baseline nonfasting glucose is <  mg/dL, fasting glucose measurement is not required
Fasting serum glucose (=<  mg/dL)
Fasting plasma glucose =<  mg/dL (=< . mmol/L) - if glucose is checked in the non fasting state and it is =<  mg/dL then this will be acceptable
Fasting plasma glucose <  mg/dL
Uncontrolled diabetes as defined by fasting glucose >. times the ULN. Note: In case this threshold is exceeded, these participants can only be included after initiation or adjustment of glucose-lowering medication.
Fasting glucose < grade  (=<  mg/dL or =< . mmol/L) without the use of antihyperglycemic agents
Free from history of chronic disease including uncontrolled diabetes (fasting blood glucose >  mg/dL), hypertension (blood pressure > / mmHg) or thyroid disease (< . or > . mIU/L); this will be determined by review of medical records and/or physician clearance
Diabetes mellitus or glucose intolerance, defined as a fasting glucose >  mg/dL
NON-CANCER PATIENT GROUP: Metabolically unhealthy: abdominal obesity + (at least one of the following: resting blood pressure above  systolic or  diastolic or anti-hypertensive medication use or fasting glucose above  mg/dL or type II diabetes mellitus)
Fasting plasma glucose =<  mg/dL (or . mmol/L)
Patients with poorly controlled diabetes mellitus with fasting serum glucose concentration over  mg/dl or a hemoglobin AC over .%.
Uncontrolled hyperglycemia as defined by any blood glucose of >  mg/dl in the past two weeks
Random glucose <  mg/dL or fasting glucose <  mg/dL (other values require workup to rule out undiagnosed diabetes that may require treatment)
Currently on medications for diabetes treatment (patients with hyperglycemia [random glucose <  mg/dL or fasting glucose <  mg/dl] but who are not on any drug treatment are eligible)
Patients with a history of or known diagnosis of diabetes according to national guidelines (fasting plasma glucose >=  mg/dL or random plasma glucose >=  mg/dL), as evidenced in laboratory values =<  months old
Fasting blood glucose =<  mg/dL
Non-fasting blood glucose >=  mg/dL, or hemoglobin AC (HbAC) >= %
Fasting blood glucose =<  mg/dL
Fasting serum glucose =<  MG/DL
Fasting plasma glucose <  mg/dL/. mmol/L
 hour fasting glucose level < . mmol/L
No known diabetes (type  or ) or baseline fasting glucose >= . mmol/L
Not frankly diabetic, as measured by a fasting blood glucose =<  mg/dL
Type I or II diabetes; documented fasting plasma glucose >  mg/dL, current exposure to antidiabetic medications, including insulin
Plasma glucose =<  mg/dL
Plasma glucose >  mg/dL
Patients with poorly controlled diabetes mellitus (fasting blood glucose level >  mg/dL)
Uncontrolled diabetes or blood glucose >  mg/dl on the day of the FDG-PET scan
Recent or current history of diabetes mellitus, defined as:) diabetes therapy within  months of enrollment, or ) fasting blood glucose at pre-admit (screening) visit >=  mg/dL
Patients with diabetes mellitus, with uncontrolled fasting blood glucose level (above  mg/dl)
Severe diabetes (fasting blood glucose >  mg/dl)
Uncontrolled diabetes mellitus (fasting glucose greater than  mg/dL)
Uncontrolled diabetes mellitus (fasting glucose >  mg/dL)
Patients with poorly controlled diabetes mellitus (fasting blood glucose level >  mg/dL)
Patient with poorly controlled diabetes (defined as fasting glucose level >  mg/dL; optimally participants will have glucose <  mg/dL) despite attempts to improve glucose control by fasting duration and adjustment of medications
Patient must not be an uncontrolled diabetic with a glucose of >=  mg/dl at the time of PET imaging
Patients with uncontrolled type II (glycosylated hemoglobin [HbAc] > % assessed locally) as judged by the investigator or abnormal fasting glucose value defined as >  mg/dL (>  mmol/L)
Uncontrolled diabetes or blood glucose >  mg/dl on the day of the fludeoxyglucose F  ([F]FDG)-PET scan
Uncontrolled hyperglycemia (defined as inability to achieve a glucose of <  mg/dL at time of FDG injection)
Blood glucose of <  mg/dL or >  mg/dL
Uncontrolled diabetes with a fasting glucose >=  mg/dl at the time of PET/MRI imaging
Serum glucose >  mg/dL
Fasting glucose >  mg/dL or
